Glaxo’s Immunotherapy Fails to Help Lung Cancer Patients
This article is for subscribers only.
An experimental GlaxoSmithKline Plc product didn’t work in a lung cancer study, the second time the medicine failed an advanced test against cancer.
The therapy known as MAGE-A3 didn’t help patients with non-small cell lung cancer live longer without the disease recurring, the London-based company said in a statement today. Glaxo plans to continue to study the treatment in a smaller group of patients who may respond better to the drug based on their genetic makeup.